Day: June 7, 2022

SOUTHAMPTON, N.Y., June 07, 2022 (GLOBE NEWSWIRE) — With easy access to the historic village’s Main Street and Job Lane, which features fine restaurants, designer boutiques and fine-art galleries, summers in Southampton are what memories are made of. Just 90 minutes from New York City, Southampton offers some of the best properties in the world, and Gin Lane is regarded by many as the finest of oceanfront locations in all of the Hamptons. One of the most classically “quintessential Hamptons” homes in the area, the sensational sea-side estate of 233 Gin Lane was designed by the esteemed architectural firm Fleetwood & McMullan. Primed for entertaining en masse courtesy of a sprawling floorplan that spans nearly 8,300 square feet, the estate includes seven bedrooms and eight bathrooms. The elegance found within its walls is expected and nods to traditional architecture and touches of minimalistic chic. The ground floor living room and dining room spill off a double-height grand foyer, leading onto a large kitchen/gathering room (one of such spaces on this level) and separate breakfast room. An elevator transports guests from the large formal and informal ground floor up to the second floor, where they are afforded sweeping views of the Atlantic Ocean.

Situated on 2.14 acres, a large sweeping driveway leads to the front of the shingle-style property, behind which all the outdoor lifestyle amenities are located for absolute privacy. These include a large, covered loggia, 25 x55′ heated swimming pool, tennis court, an allee’ of flowering trees and sweeping lawns. 233 Gin Lane is perfectly suited for both full-time living, weekend getaways or long summer vacations from the city – a seaside sanctuary for a water-lover who enjoys welcoming good company and an active cultural roster that includes open-air concerts, local fireworks displays and a rich list of well-planned social events throughout the year.

233 Gin Lane, Southampton, NY is offered at $26,000,000. For more information and a private showing, please contact Licensed Associate Real Estate Broker Tim Davis of the Corcoran Group at tgdavis@corcoran.com, timdavishamptons.com.

About Tim Davis

Power Broker and lifelong Hamptons resident Tim Davis boasts an accomplished 40+ year real estate career listing and selling some of the finest properties on the East End.

Contact Information

For more information, please contact:

Tim Davis, Licensed Associate Real Estate Broker

Corcoran Group Real Estate
24 Main Street Southampton, NY 11968
T: +1 631.702.9211 or +1 516.356.5736
E: tgdavis@corcoran.com

Related Images

Image 1: 233 Gin Lane Southampton Aerial

233 Gin Lane Southampton Aerial

This content was issued through the press release distribution service at Newswire.com.

Attachment

• 233 Gin Lane Southampton Aerial

June 7, 2022

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA) today announced that the exchange ratio for the dividend in shares for the year 2021 has been determined. The exchange ratio is 1 new common share for every 27.3184 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of June 1, 2 and 3, 2022, of EUR 23.1906 and was calculated in a manner that the gross dividend in shares is approximately equal to the gross dividend in cash.

Shareholders were given the opportunity to make their choice between cash and shares between May 16, 2022 and June 3, 2022. If no choice was made during this election period, the dividend will be paid in cash. Both the dividend in cash and the dividend in shares will be made payable to shareholders from June 8, 2022.

For 44.5% of the currently outstanding shares, an election was made for a share dividend, resulting in the issuance of 14,174,568 new common shares. Upon distribution of the dividend shares, the total issued share capital will amount to EUR 179,614,707.40, representing 898,073,537 common shares.

As communicated earlier, Philips intends to have 19,571,218 shares delivered through the early settlement of forward contracts in the remainder of 2022. These forward contracts were entered into as part of the EUR 1.5 billion share repurchase program for capital reduction purposes, as announced on July 26, 2021. Philips expects to cancel a total of 28,329,673 shares (including 8,758,455 treasury shares already held) before the end of the year, which would result in 869,743,864 issued common shares at year-end 2022 (2021: 883,898,969). More information is available via this link.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 15213446
E-mail: ben.zwirs@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 79,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

LONDON and AMSTERDAM, June 07, 2022 (GLOBE NEWSWIRE) — Trust Payments, the disruptive leader in fintech specialising in frictionless payments and value-added services, announced today at Money20/20 Europe a multi-year partnership with Feedzai, the world’s first RiskOps platform for financial risk management. Using Feedzai, a key market leader in safeguarding global commerce, Trust Payments’ customers will benefit from an advanced cloud-based risk management platform, powered by machine learning and artificial intelligence.

Feedzai’s RiskOps meets key industry challenges to seamlessly solve for identity, real-time data, and collaboration across the customer lifecycle whilst increasing productivity and enabling financial services companies to deliver better outcomes for their customers.

Daniel Holden, Group CEO of Trust Payments, said: “We’re delighted to be partnering with Feedzai to ensure our vision for Converged Commerce™ can be backed by their robust risk management offering, covering device authentication, malware defense, behavioral biometrics, and a full suite of integrated fraud and anti-money laundering solutions. This partnership will reinforce our commitment to a gold-standard risk framework to help deliver trusted commerce solutions to our customers around the world.”

“We are delighted that Trust Payments has selected Feedzai as a trusted partner and is implementing our unique RiskOps solution to ensure that their teams have a single platform to handle everything fraud and financial crime-related and to ensure financial security for themselves and their customers,” added Nuno Sebastião, CEO at Feedzai.

The world’s largest banks, processors, and retailers already trust Feedzai to protect trillions of dollars and manage risk while improving the customer experience for everyday users, without compromising privacy. Feedzai is a Series D company and has raised $282M to date with a current valuation of $1.5B. Its technology protects 900 million people in 190 countries.

About Trust Payments:
Trust Payments is a disruptive leader in fintech, specialising in frictionless payments and value-added services for online and offline merchants. We provide on-demand Payments and Banking-as-a-Service services to help businesses grow and scale online, in-store, and on mobile.

Trust Payments combines these omnichannel services with powerful tools, such as retail operations technology, loyalty management and instant eCommerce. We are constantly engaging new innovative payment methods in crypto and bank transfers to drive Converged Commerce™. Since 2020, Trust Payments has acquired multiple businesses into its Group including WonderLane (retail operations and point of sale leaders); Stor (full e-commerce platform designed for small merchants); and Mobilize (specialists in mobile-based engagement and loyalty tracking).

Focusing on any commerce providers in the UK, EU and US, Trust Payments drives value for our clients through personalised services, secure and frictionless payments, and innovative products. Small and medium sized enterprises particularly benefit from our 24 years’ expertise.

Trust Payments has a global footprint, with over 500 people across 11 offices supporting the most demanding business sectors ­– from retail, travel and hospitality to crypto, gaming, and financial services. We have an acquiring network of over 50 global banks and hundreds of alternative payment methods.

We hold Visa and Mastercard Principal Memberships in the EU for cross-border business, are licenced by both the Malta Financial Services Authority and the UK Financial Conduct Authority and holds licences in 6 US States to carry out regulated payments in gaming.

Find out more at www.trustpayments.com.

About Feedzai:
Feedzai is the world’s first RiskOps platform for financial risk management, and the market leader in safeguarding global commerce with today’s most advanced cloud-based risk management platform, powered by machine learning and artificial intelligence. Feedzai is securing the transition to a cashless world while enabling digital trust in every transaction and payment type. The world’s largest banks, processors, and retailers trust Feedzai to protect trillions of dollars and manage risk while improving the customer experience for everyday users, without compromising privacy. Feedzai is a Series D company and has raised $282M to date with a current valuation of $1.5B. Its technology protects 900 million people in 190 countries. For more information, visit feedzai.com

Media Contact:
Catarina da Fonseca
PR & Communications Manager, Feedzai
catarina.fonseca@feedzai.com

Joe Fernandez
Content & Communications Manager, Trust Payments
joe.fernandez@trustpayments.com

June 7, 2022

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Willem (Wim) Appelo will join Philips’ Executive Committee, effective July 18, 2022, and succeed Sophie Bechu as Chief Operations Officer per October 1, 2022. Mr. Appelo will report to Philips CEO Frans van Houten and work closely with Mrs. Bechu to ensure a seamless transition. Mrs. Bechu, who joined Philips in 2016, will step down from her role on October 1, 2022, after which she will work on project-based initiatives until she retires at the end of January, 2023.

Mr. Appelo (Dutch, 1964) will join Philips after having worked as interim Supply Chain Officer, and with private equity firms in the medical technology industry for the last year. Before that, he was Vice President Supply Chain Strategy, Innovation & Deployment at Johnson & Johnson, where he led the Enterprise Supply Chain Global Strategy and Innovation team across the company’s three operating segments: Pharma, Consumer Health, and Medical Devices. Prior to that, Mr. Appelo was Johnson & Johnson’s Vice President Supply Chain Medical Devices. Prior to joining Johnson & Johnson, he held various senior positions at Xerox Corporation, ultimately as President, Global Delivery and Technology Group, where he was responsible for Xerox’s then newly-created Global Supplies Business Group.

“I am very pleased that Wim Appelo will be joining Philips as our new Chief Operations Officer,” said Frans van Houten, CEO of Royal Philips. “Wim brings a wealth of relevant experience to Philips, adding in-depth knowledge and understanding of medical technology and informatics supply chain management, which will help Philips accelerate its journey to becoming a health technology solutions leader. I want to thank Sophie for her highly valuable contribution to Philips and her relentless focus and deep commitment to establishing Philips’ Integrated Supply Chain organization since joining in 2016. During that time, she successfully optimized our supplier base and manufacturing footprint, continually driving operational excellence with a customer-first mindset.”

Mr. Appelo’s appointment to Philips’ Executive Committee builds on last year’s appointment of Shez Partovi, MD, as Chief Medical, Innovation & Strategy Officer, and member of Philips’ Executive Committee. Dr. Partovi brings highly relevant experience to Philips given his prior roles as neuroradiologist at the Barrow Neurological Institute, Chief Digital Officer at Dignity Health, and Worldwide Head of Healthcare, Life Sciences and Medical Devices at Amazon Web Services (AWS). Philips has continued to strengthen its senior management across the company with the appointment of 30 experienced healthcare and medical technology leaders over the past three years.

Additional information on Philips’ Executive Committee can be found here.

For further information, please contact:

Ben Zwirs
Philips Global Press Office
Tel.: +31 6 1521 3446
E-mail: ben.zwirs@philips.com

Derya Guzel
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: derya.guzel@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 79,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

• Willem Appelo

Keeping an eye on the world market: crop.zone strengthens its capital base for serial production

AACHEN, Germany, June 07, 2022 (GLOBE NEWSWIRE) — Good news for herbicide-free agriculture. crop.zone, manufacturer of the volt.fuel Electrical Weeding System, has significantly strengthened its capital base for entering into serial production.

Existing shareholders (incl. Nufarm Limited) and new financial investors (Demeter Investment Managers, Madaus Capital Partners) have increased the equity base of the Aachen-based company by almost 11 million USD.

The innovative crop.zone system offers a natural organic alternative to non-selective synthetic herbicides such as Glyphosate or Diquat. As a highly productive and efficient solution, it is also used in desiccation applications and seedbed preparation.  crop.zone’s system is currently being successfully applied in Europe. It is available through crop.zone’s partners Nufarm, Kamps de Will and fenaco.

crop.zone’s and investors’ objectives for the USD 11 million investment are to open up new international markets and to develop additional agronomic treatment patterns for the crop.zone system.

“Our focus is investing in people, production and scaling. crop.zone will change agriculture by giving the industry a tool to work in a more sustainable and organic manner. Our ambition is to rethink the way we farm,” says CEO Dirk Vandenhirtz, highlighting the key issue that agriculture faces today and that crop.zone aims to address with its renewed investment.

Intellectual property is the key when starting serial production of the system, which is already in use in Germany, the Netherlands and Switzerland.

“We see the new investment as a great vote of confidence from our partners which shows a high level of trust in the path to a product ready for serial production. crop.zone is now a mature technology that solves problems in international agriculture. It is easy for farmers to use, renders the use of harmful herbicides superfluous and enables  a major contribution to CO2-reduced agriculture,” Dirk Vandenhirtz continues.

crop.zone’s existing shareholders, who have co-invest in the current financing round, include Nufarm Limited, a leading developer and manufacturer of crop protection solutions and seed technologies. The company, which has more than 2,500 employees, serves major agricultural markets in Europe, North America and Asia Pacific and is headquartered in Melbourne, Australia. Nufarm Regional General Manager EuMEA, Hildo Brilleman, says that Nufarm was proud to strengthen its existing partnership with crop.zone as it continues to build on its expanding portfolio of sustainable solutions for farmers:

“This new funding round allows crop.zone to expand their technology into new crops and segments. We are proud to be part of this journey to develop a sustainable potato desiccation and weed control offer for European farmers. Full commercialization of NUCROP will begin this year after a successful trial season in various European countries. As a key partner for commercialization, Nufarm will market the crop.zone solution under its own brand NUCROP across our distribution partners for Ag inputs and farm equipment.”

The investment by Demeter Investment Managers, a major European player in venture capital and private equity for the ecological transition, shows the importance of crop.zone system’s unique selling point – an alternative to pesticides in farming. Demeter Managing Partner Cyrille Cabaret says:

“At Demeter Investment Managers, we believe there is an urgent need to find alternatives to chemical non-selective herbicides in agriculture. The electrical hybrid technology developed by crop.zone offers farmers an effective, competitive, and organic solution for crop management. We are thrilled to accompany the crop.zone team in this new development phase alongside renowned partners like Nufarm, LBBZ and Madaus Capital Partners.”

Through its subsidiary RWTH Innovation, RWTH continues to support crop.zone in the current financing round. crop.zone had already been supported to get going by participating in the RWTH Innovation Sprint, a pre-seed funding mechanism by RWTH Innovation supported by the Exzellenz Start-up Center.NRW initiative of the NRW Ministry for Economic Affairs. The Innovation Sprint helped crop.zone to build a prototype and thus validate the business case of their technology.

“Then, as now, the potential of an environmentally impactful technology embedded in the regional research and innovation ecosystem and run by a team with a profound industry expertise has been the key argument for us to get involved”, says Bram Wijlands, Managing Director at RWTH Innovation. “This technology fully embodies the spirit of RWTH Aachen being the seedbed for profound tech innovations.”

Further information please contact us at
info@crop.zone crop.zone PR

• Germany:  +49 2408 59 80 333
• Netherlands:  +31 850659277
• France:   +33 0970 445 443
• United States: +1 (919) 251 -6320
• Switzerland: +41 (44) 585 34 88
• Hong Kong SAR: +852 8193 0287
• United Kingdom: +44 020 8133 7059

Related Images

Image 1: Dirk Vandenhirtz CEO – Founder

Dirk Vandenhirtz CEO and founder of crop.zone

This content was issued through the press release distribution service at Newswire.com.

Attachment

• Dirk Vandenhirtz CEO – Founder

GHENT, Belgium, June 07, 2022 (GLOBE NEWSWIRE) — MRM Health, a clinical-stage biopharmaceutical company developing next-generation live microbiome consortia therapeutics, announces the publication of preclinical research relating to its ongoing program in non-alcoholic fatty liver disease (NAFLD), with a 9-strain live bacterial consortium resulting from its proprietary and unique CORAL^® platform technology.

The research was conducted in collaboration with the lab of leading experts Dr. Salvador Augustin (MD) and Dr. Maria Martell of the Liver Unit within the Department of Internal Medicine at the University Hospital of Vall d’Hebron (Barcelona, Spain). The work demonstrates that a live bacterial consortium of 9 rationally selected gut commensal strains was able to improve portal hypertension, insulin signaling and NAFLD activity score at histopathology and to prevent fibrosis development in two different in vivo disease models of Non-Alcoholic Steatohepatitis (NASH). The bacterial consortium also improved endothelial function and re-balanced the gut microbiome in the disease models.

NAFLD, and its progressive form NASH, is the hepatic manifestation of the metabolic syndrome and has a rapidly increasing prevalence, with about 20-30% of the general adult population suffering from NAFLD. Progression of NAFLD into NASH and cirrhosis becomes irreversible, yet no registered treatment is available to date. Leveraging on its breakthrough CORAL^® platform, MRM Health identified and developed the 9-strain bacterial consortium, based on a combination of mechanisms-of-action linked to NAFLD.

“These preclinical results are highly important as there are to date no approved therapies for NASH or portal hypertension and the field urgently needs new approaches,” commented Dr. Maria Martell “Microbiome-based manipulation of the gut-liver axis can offer a completely novel treatment strategy for NASH and holds much promise for the full spectrum of liver disease”.

“We believe live bacterial consortia have transformational potential for metabolic and liver diseases,” said Nigel Horscroft, D.Phil., Chief Scientific Officer of MRM Health. “These recent advancements from MRM Health scientists and our academic partner highlight the potential of Live Biotherapeutic Products developed through our CORAL^® platform to impact serious diseases, including NASH and Ulcerative Colitis (UC), upon which existing therapeutic modalities have had little impact.”

The results will also be presented as a poster at the International Liver Congress 2022 in London (UK), June 22-26, 2022.

Publication: Pinheiro et al. 2022, Biomedicines, A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo (https://www.mdpi.com/2227-9059/10/5/1191#)

About MRM Health

MRM Health NV, Ghent, Belgium, is a biopharmaceutical company focused on the development of next-generation optimized consortium therapeutics based on the human microbiome. The company has built a diversified pipeline with its proprietary CORAL^® platform to design, optimize, and manufacture bacterial consortia as single drug substance. Its most advanced program MH002 is an optimized consortium of 6 rationally-selected and well-characterized commensal strains. MH002 is currently being studied in a Phase 1b/2a study in patients with mild-to-moderate ulcerative colitis and a second clinical study is in start-up. Additional pipeline development includes a preclinical program in Parkinson’s disease, preclinical programs in Type 2 Diabetes and in NAFLD (both partnered with IFF Nutrition Biosciences, previously DuPont), and a discovery program in autoimmune disease, including spondyloarthritis.

About CORAL^®

MRM Health’s differentiating CORAL^® platform utilizes a bioinformatics-guided in-human discovery engine combined with a breakthrough in optimization and manufacturing of consortia as single drug substance. The proprietary consortia optimization technology allows to develop next-generation consortia therapeutics with faster onset-of-action and increased potency and robustness. The breakthrough scalable, robust, and standardized cGMP-compliant consortia manufacturing technology allows to manufacture complete therapeutic consortia as a single drug substance in a single manufacturing process which strongly surpasses existing approaches in speed, reduced complexity, increased robustness and lower cost.

For further information please contact:

Dr Sam Possemiers – CEO
Christiane Verhaegen – CFO
Phone: +32.9.277.08.50
info@mrmhealth.com